1. Signaling Pathways
  2. Immunology/Inflammation
  3. Kallikrein
  4. Kallikrein Isoform

Kallikrein

 

Kallikrein Related Products (27):

Cat. No. Product Name Effect Purity
  • HY-16735
    Avoralstat
    Inhibitor ≥98.0%
    Avoralstat (BCX4161), a potent and orally active plasma kallikrein (PKK) inhibitor, is used for hereditary angioedema research.
  • HY-P99110
    Lanadelumab
    Inhibitor 99.90%
    Lanadelumab (SHP643) is a human IgG1 monoclonal antibody against plasma kallikrein (pKal) with an Ki value of 0.12 nM. Lanadelumab inhibits both free and HMWK (high molecular weight kininogen)-bound pKal. Lanadelumab has the potential for the research of hereditary angioedema.
  • HY-132830
    Sebetralstat
    Inhibitor 99.58%
    Sebetralstat (KVD900) is a plasma kallikrein inhibitor (WO2016083820). Sebetralstat can be used for the research of metabolic diseases.
  • HY-148949
    Kallikrein 5-IN-2
    98.96%
    Kallikrein 5-IN-2 (compound 21) is a selective Kallikrein KLK5 inhibitor (pIC50=7.1). KLK5 inhibition may normalise epidermal shedding and reduce the associated inflammation and itching.
  • HY-109127
    Berotralstat
    Inhibitor 99.70%
    Berotralstat (BCX7353) is an orally active plasma kallikrein inhibitor. Berotralstat can reduce brain edema and is being studied for glioblastoma and hereditary angioedema.
  • HY-P4245
    D-Pro-Phe-Arg-Chloromethylketone
    Inhibitor 99.24%
    D-Pro-Phe-Arg-Chloromethylketone, a inhibitor of coagulation factor XII and plasma kallikrein, plays an important role in thrombosis and inflammation.
  • HY-108814A
    Ecallantide TFA
    Inhibitor 98.63%
    Ecallantide (DX-88) TFA is a specific recombinant plasma kallikrein inhibitor. Ecallantide inhibits the production of bradykinin. Ecallantide may be used to prevent acute attacks of angioedema.
  • HY-109127A
    Berotralstat dihydrochloride
    Inhibitor 98.49%
    Berotralstat dihydrochloride (BCX7353 dihydrochloride) is an orally active plasma kallikrein inhibitor. Berotralstat can reduce brain edema and is being studied for glioblastoma and hereditary angioedema.
  • HY-123133
    PKSI-527
    Inhibitor 98.08%
    PKSI-527 is a new, highly selective plasma kallikrein inhibitor. PKSI-527 can suppress collagen-induced arthritis (CIA) by modifying the kallikrein-kinin system.
  • HY-P0237A
    KKI-5 TFA
    98.74%
    KKI-5 (TFA) is a specific inhibitor of tissue kallikrein. KKI-5 (TFA) can attenuate breast cancer cell invasion.
  • HY-145568
    Feniralstat
    Inhibitor 99.87%
    Feniralstat (compound 30), a pyrazole derivative, is a potent kallikrein inhibitor with an IC50 of 6.7 nM for Human plasma kallikrein (pKal). Feniralstat has no inhibition on Human KLKl, Human FXIa, Human Factor Xlla (all IC50>40 μM).
  • HY-153115
    Plasma kallikrein-IN-4
    Inhibitor 98.61%
    Plasma kallikrein-IN-4 (Example 153) is a plasma kallikrein inhibitor with an IC50 of 0.016 μM against human plasma kallikrein.
  • HY-114150D
    D-Val-Leu-Arg-pNA acetate
    99.75%
    D-Val-Leu-Arg-pNA (acetate) is the acetate form of D-Pro-Phe-Arg-p-nitroanilide (pNa). D-Pro-Phe-Arg-p-nitroanilide (pNa) is the substrate for kallikrein and can be used to assay the activity of kallikrein.
  • HY-122543
    PPACK II diTFA
    Inhibitor
    PPACK II diTFA is an irreversible and specific glandular and plasma kallikreins inhibitor.
  • HY-126378
    LSP-249
    Inhibitor 99.05%
    LSP-249 (example 35), extracted from patent WO2016011209A1, is a plasma kallikrein inhibitor under the study for angioedema, with an EC50 less than 100 nM in cell.
  • HY-139888
    Plasma kallikrein-IN-1
    Inhibitor
    Plasma kallikrein-IN-1 is a PKK inhibitor with an IC50 value of 0.5 nM.
  • HY-108814
    Ecallantide
    Inhibitor
    Ecallantide (DX-88) is a specific plasma kallikrein inhibitor. Ecallantide inhibits the production of bradykinin. Ecallantide can be used to prevent acute attacks of angioedema.
  • HY-P990459
    Anti-KLK5/Kallikrein 5 Antibody
    Inhibitor
    Anti-KLK5/Kallikrein 5 Antibody is a CHO-expressed human antibody that targets KLK5/Kallikrein 5. The Anti-KLK5/Kallikrein 5 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-KLK5/Kallikrein 5 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
  • HY-122543A
    PPACK II
    Inhibitor
    PPACK II is an irreversible and specific glandular and plasma kallikreins inhibitor.
  • HY-139787A
    Donidalorsen sodium
    Inhibitor
    Donidalorsen (sodium) is an antisense oligonucleotide designed to reduce the production of prekallikrein (PKK). PKK plays an important role in the activation of inflammatory mediators associated with acute attacks of Hereditary angioedema (HAE).